In today's m&a news, Perrigo Company announced today that it will acquire Belgium-based Omega Pharma for $4.5 billion.
Perrigo develops, manufactures and distributes over-the-counter and generic prescription drugs, nutritional products and active pharmaceutical ingredients.
Omega is an over-the-counter healthcare company that operates in 35 countries across Europe and certain emerging markets.
The deal is a mix of cash and equity valued at $4.5 billion.
Perrigo will purchase Omega’s equity for €2.48 billion and take on €1.1 billion in debt.
Twenty-five percent of the equity purchase price will be funded by Perrigo stock, about 5 million shares, going directly to Coucke, and 75 percent will be funded via a combination of cash and debt.
J.P. Morgan Chase Bank, N.A. and Barclays have provided Perrigo with a €1.75 billion bridge.
The transaction has been unanimously approved by both companies’ boards and is expected to close in the first quarter of 2015.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity